News

Yilei Laser Reports Strong Order Backlog and Expands into AI and Humanoid Robotics (June 18, 2025)

At its 2025 performance briefing, Yilei Laser reported a strong order backlog, with a significant portion from large cylindrical full-tab battery assembly lines and overseas market breakthroughs. The company made substantial progress in solid-state battery equipment, perovskite solar, and semiconductor AMHS systems. Yilei is actively expanding into humanoid robotics, co-founding Hubei Jingchu Humanoid Robot Co., Ltd., to commercialize intelligent manufacturing and embodied intelligence technologies. R&D expenses reached RMB 93 million in 2024, with a 67.77% year-on-year increase in Q1 2025.

News Link: https://cj.sina.com.cn/articles/view/1704103183/65928d0f02008ac82

September 26, 2024

Pillar Biosciences Partners with AstraZeneca to Accelerate Access to Liquid Biopsy Testing (September, 2024)

In September 2024, Pillar Biosciences announced a strategic partnership with AstraZeneca to expand laboratory access to molecular testing in Europe and the UK using rapid, affordable NGS-based liquid biopsy tumor profiling kits. The collaboration leverages Pillar’s oncoReveal™ liquid biopsy panels to deliver highly sensitive and specific tumor genetic varia

June 26, 2025

Based on the SIPS model ChangYi proposes marketing strategies for big health brands

According to the “Gen Z Nutrition Consumption Trend Report,” consumers aged 18-35 account for 83.7% of the total health and wellness market, becoming the main force driving growth. Driven by the “Healthy China” initiative and shifting health awareness, the industry is rapidly developing amid fierce competition. Marketing focus has shifte

January 7, 2025

Leto Laboratories Developing Semaglutide Biosimilar for Diabetes, Currently in Phase II Clinical Trial (2025)

Leto Laboratories is developing a Semaglutide biosimilar for diabetes and weight loss treatment, currently in Phase II clinical trials. The therapeutic candidate targets the GLP-1 receptor. According to GlobalData, Phase II diabetes drugs have a 38% success rate to advance to Phase III. Leto leverages its high-throughput screening and directional protein refold

December 26, 2024

MDHC Technologies Secures Series B Funding to Accelerate Growth and Innovation (2024)

MDHC Technologies completed a Series B funding round with investors including Chery Automobile, LAKSIMI Capital, Lucion Venture Capital Group, Yongxin Fangzhou, Addor Capital, and others. The funding will accelerate the development of its intelligent manufacturing platform, expand production capacity, and increase R&D investment, driving innovation and mark

Yilei Laser Reports Strong Order Backlog and Expands into AI and Humanoid Robotics (June 18, 2025)

Leave a Reply Cancel reply

Valiance theme

Yilei Laser Reports Strong Order Backlog and Expands into AI and Humanoid Robotics (June 18, 2025)

Related Posts

Pillar Biosciences Partners with AstraZeneca to Accelerate Access to Liquid Biopsy Testing (September, 2024)

Based on the SIPS model ChangYi proposes marketing strategies for big health brands

Leto Laboratories Developing Semaglutide Biosimilar for Diabetes, Currently in Phase II Clinical Trial (2025)

MDHC Technologies Secures Series B Funding to Accelerate Growth and Innovation (2024)

Leave a Reply Cancel reply

Valiance theme